tiprankstipranks
The Fly

2seventy Bio downgraded to Market Perform from Outperform at Leerink

2seventy Bio downgraded to Market Perform from Outperform at Leerink

Leerink downgraded 2seventy Bio (TSVT) (TVST) to Market Perform from Outperform with a price target of $5, down from $9, to reflect the pending takeover by Bristol Myers (BMY). The firm does not expect an alternative acquirer will emerge, and thinks the transaction with Bristol will close.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com